featured
Renal Response Better With Carfilzomib vs Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Response in Real-World Carfilzomib- vs Bortezomib-Treated Patients With Relapsed or Refractory Multiple Myeloma
Blood Adv 2021 Jan 26;5(2)367-376, S Kumar, A Fu, R Niesvizky, S Jagannath, R Boccia, N RajeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.